<div id="readability-page-1"><p>Central Pacific Bank Trust Division lowered its stake in shares of  Insulet Corporation (NASDAQ:PODD - Free Report) by 99.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 480 shares of the medical instruments supplier's stock after selling 291,000 shares during the quarter. Central Pacific Bank Trust Division's holdings in Insulet were worth $148,000 at the end of the most recent quarter.</p><ul><li>3 Medical Technology Stocks Outperforming in 2025</li></ul><p>A number of other institutional investors also recently bought and sold shares of PODD. Kozak &amp; Associates Inc. bought a new stake in shares of  Insulet in the 2nd quarter worth about $32,000.  Golden State Wealth Management LLC lifted its stake in  Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 69 shares during the last quarter.  Trust Co. of Toledo NA OH purchased a new position in shares of  Insulet during the second quarter valued at approximately $35,000.  Osterweis Capital Management Inc. bought a new position in shares of  Insulet during the second quarter valued at approximately $51,000.  Finally, NewEdge Advisors LLC raised its holdings in shares of  Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier's stock worth $54,000 after buying an additional 64 shares during the period. </p><h2>Insulet Stock Up 0.3%</h2><p>Shares of Insulet stock opened at $289.57 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18. The stock has a market cap of $20.37 billion, a price-to-earnings ratio of 83.93, a PEG ratio of 2.03 and a beta of 1.37. The firm's 50-day moving average is $317.47 and its two-hundred day moving average is $314.16. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88. </p><ul><li>Insulet Surges on Q1 Beat, Emerges as a Top S&amp;P 500 Performer</li></ul><p>Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The business had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. During the same quarter in the previous year, the business posted $1.08 EPS. The company's quarterly revenue was up 29.9% compared to the same quarter last year.  As a group, research analysts expect that  Insulet Corporation will post 3.92 earnings per share for the current fiscal year. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several equities analysts have commented on PODD shares. BTIG Research upped their price objective on Insulet from $370.00 to $380.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, November 21st. Jefferies Financial Group upped their price target on shares of Insulet from $375.00 to $400.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, November 6th. Evercore ISI started coverage on shares of Insulet in a research note on Tuesday. They issued an &#34;outperform&#34; rating and a $370.00 price target on the stock. Oppenheimer boosted their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, September 8th. Finally, Rothschild &amp; Co Redburn raised their target price on shares of Insulet from $350.00 to $370.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, October 3rd. One equities research analyst  has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned  a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $380.05.</p><ul><li>Are These 5 Undervalued Stocks Ready to Break Out?</li></ul><p><b>Get Our Latest Research Report on Insulet</b></p><h2>Insulet Profile</h2> (Free Report)<p>Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.</p><h2>Read More</h2><ul><li>Five stocks we like better than Insulet</li><li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li><li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li><li>Value Investing: Is it a Good Strategy in 2022? <span>Hint: Always<span></span></span></li><li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li><li>5 Top Rated Dividend Stocks to Consider</li><li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li></ul><p><strong>Want to see what other hedge funds are holding PODD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UE9ERA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UE9ERA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Insulet Right Now?</h2><p>Before you consider Insulet, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.</p><p>While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PODD

<p>Central Pacific Bank Trust Division reduced its stake in Insulet Corporation by 99.8% in the third quarter, selling 291,000 shares and retaining 480 shares valued at $148,000. Despite this, Insulet's stock performance remains strong, with analysts maintaining a 'Moderate Buy' rating and a consensus target price of $380.05. The company reported a 29.9% increase in quarterly revenue year-over-year.</p>

Central Pacific Bank Trust Division Reduces Stock Holdings in Insulet Corporation $PODD